Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

Next Previous
Trial Profile

A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Artesunate (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Imatinib (Primary) ; Infliximab (Primary) ; Metablok-Arch Biopartners (Primary) ; Lopinavir/ritonavir
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms CATCO

Most Recent Events

  • 12 Oct 2023 Planned primary completion date changed from 18 Mar 2023 to 10 Mar 2024.
  • 12 Oct 2023 Status changed from recruiting to active, no longer recruiting.
  • 26 Apr 2022 Treatments section has been updated to replace Losartan with Angiotensin II receptor blockers. The type of ARB received will be dependent on what is available at the hospitals.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top